HHS’ commitment to transparency

Executive Summary

Concerns about FDA's regulation of drug safety will not need a legislative fix, HHS Secretary Michael Leavitt told the Pharmaceutical Research & Manufacturers of America annual meeting in Washington, D.C. March 17. HHS hopes to use the Medicare program as one instrument to help improve data collection to support post-marketing surveillance, Leavitt said. He also stressed the importance of increasing the transparency of FDA's approach to drug safety issues. Leavitt's luncheon address was closed to the media...